Literature DB >> 8546207

Altered presynaptic protein NACP is associated with plaque formation and neurodegeneration in Alzheimer's disease.

E Masliah1, A Iwai, M Mallory, K Uéda, T Saitoh.   

Abstract

We have recently identified, in the brain tissue of patients afflicted with Alzheimer's disease (AD), the non-A beta component of AD amyloid (NAC) as a new constituent of amyloid. NAC is derived from a larger precursor, NACP, a presynaptic protein. To better understand the role of NACP/NAC in the pathogenesis of AD, we used semiquantitative immunoblotting and combined double-immunocytochemistry/laser scanning confocal microscopy to study the concentration and distribution of NACP/NAC in human brain, and compared them to the concentration and distribution of the presynaptic marker synaptophysin and the amyloid marker A beta. The semiquantitative immunoblotting demonstrated that the NACP concentration is slightly increased in the AD frontal cortex without statistical significance, whereas synaptophysin was reduced in its levels in AD. Consequently the proportion of NACP/synaptophysin was more than double in the AD frontal cortex as compared with controls. In the AD neocortex, NACP was colocalized with approximately 80% of the synaptophysin-immunoreactive structures (presumably the presynaptic terminals) and with the dystrophic neuritic component of the plaques. Computer-aided analysis showed that numbers of NACP-immunoreactive structures along synaptophysin-immunoreactive structures were significantly diminished (30 to 40%) in AD. Although the overall numbers of NACP-positive structures were decreased, there was a significant increase in the intensity of NACP-immunoreactivity per structure in AD. This increased intensity of NACP immunoreactivity per structure in AD was not observed with anti-synaptophysin, consistent with immunoblotting-based quantification. Antibodies against NAC immunoreacted with amyloid in 35% of the diffuse plaques and 55% of the mature plaques. Normal aged control brains containing small groups of diffuse plaques were negative with anti-NAC. Double-immunolabeling studies with A beta antibodies showed that NAC immunoreactivity is more abundant in the center portion of amyloid rather than in the periphery. These studies suggest that there is a connection between metabolism of presynaptic proteins and amyloid formation, and that NAC might follow diffuse A beta accumulation resulting in the formation of compact amyloid and mature plaques.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8546207      PMCID: PMC1861620     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  35 in total

1.  Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport.

Authors:  E H Koo; S S Sisodia; D R Archer; L J Martin; A Weidemann; K Beyreuther; P Fischer; C L Masters; D L Price
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

2.  Cyanine dye labeling reagents containing isothiocyanate groups.

Authors:  R B Mujumdar; L A Ernst; S R Mujumdar; A S Waggoner
Journal:  Cytometry       Date:  1989-01

3.  A neuronal antigen in the brains of Alzheimer patients.

Authors:  B L Wolozin; A Pruchnicki; D W Dickson; P Davies
Journal:  Science       Date:  1986-05-02       Impact factor: 47.728

4.  A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease.

Authors:  C A Davies; D M Mann; P Q Sumpter; P O Yates
Journal:  J Neurol Sci       Date:  1987-04       Impact factor: 3.181

5.  Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein.

Authors:  G G Glenner; C W Wong
Journal:  Biochem Biophys Res Commun       Date:  1984-05-16       Impact factor: 3.575

6.  Lysosomal proteinase antigens are prominently localized within senile plaques of Alzheimer's disease: evidence for a neuronal origin.

Authors:  A M Cataldo; C Y Thayer; E D Bird; T R Wheelock; R A Nixon
Journal:  Brain Res       Date:  1990-04-16       Impact factor: 3.252

7.  Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity.

Authors:  S T DeKosky; S W Scheff
Journal:  Ann Neurol       Date:  1990-05       Impact factor: 10.422

8.  Quantitative assessment of cortical synaptic density in Alzheimer's disease.

Authors:  S W Scheff; S T DeKosky; D A Price
Journal:  Neurobiol Aging       Date:  1990 Jan-Feb       Impact factor: 4.673

9.  Identification and localization of synaptophysin, an integral membrane glycoprotein of Mr 38,000 characteristic of presynaptic vesicles.

Authors:  B Wiedenmann; W W Franke
Journal:  Cell       Date:  1985-07       Impact factor: 41.582

10.  Immunochemical identification of the serine protease inhibitor alpha 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease.

Authors:  C R Abraham; D J Selkoe; H Potter
Journal:  Cell       Date:  1988-02-26       Impact factor: 41.582

View more
  45 in total

1.  The role of NAC in amyloidogenesis in Alzheimer's disease.

Authors:  M Hashimoto; T Takenouchi; M Mallory; E Masliah; A Takeda
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

2.  Lentivirus mediated delivery of neurosin promotes clearance of wild-type α-synuclein and reduces the pathology in an α-synuclein model of LBD.

Authors:  Brian Spencer; Sarah Michael; Jay Shen; Kori Kosberg; Edward Rockenstein; Christina Patrick; Anthony Adame; Eliezer Masliah
Journal:  Mol Ther       Date:  2012-04-17       Impact factor: 11.454

Review 3.  Multiple system atrophy: a clinical and neuropathological perspective.

Authors:  Kiren Ubhi; Phillip Low; Eliezer Masliah
Journal:  Trends Neurosci       Date:  2011-09-29       Impact factor: 13.837

4.  Specific antibodies to soluble alpha-synuclein conformations in intravenous immunoglobulin preparations.

Authors:  L M Patrias; A C Klaver; M P Coffey; D A Loeffler
Journal:  Clin Exp Immunol       Date:  2010-09       Impact factor: 4.330

5.  Insoluble alpha-synuclein in Alzheimer's disease without Lewy body formation.

Authors:  Melissa Broe; Claire E Shepherd; David M A Mann; Elizabeth A Milward; Wei-Ping Gai; Emma Thiel; Glenda M Halliday
Journal:  Neurotox Res       Date:  2005       Impact factor: 3.911

Review 6.  Single cell gene expression profiling in Alzheimer's disease.

Authors:  Stephen D Ginsberg; Shaoli Che; Scott E Counts; Elliott J Mufson
Journal:  NeuroRx       Date:  2006-07

Review 7.  The role of lipids in α-synuclein misfolding and neurotoxicity.

Authors:  Cathryn L Ugalde; Victoria A Lawson; David I Finkelstein; Andrew F Hill
Journal:  J Biol Chem       Date:  2019-05-07       Impact factor: 5.157

Review 8.  α-Synuclein nonhuman primate models of Parkinson's disease.

Authors:  David J Marmion; Jeffrey H Kordower
Journal:  J Neural Transm (Vienna)       Date:  2017-04-22       Impact factor: 3.575

Review 9.  The many faces of α-synuclein: from structure and toxicity to therapeutic target.

Authors:  Hilal A Lashuel; Cassia R Overk; Abid Oueslati; Eliezer Masliah
Journal:  Nat Rev Neurosci       Date:  2013-01       Impact factor: 34.870

10.  Caspase-3 is enriched in postsynaptic densities and increased in Alzheimer's disease.

Authors:  Natalia Louneva; Julia W Cohen; Li-Ying Han; Konrad Talbot; Robert S Wilson; David A Bennett; John Q Trojanowski; Steven E Arnold
Journal:  Am J Pathol       Date:  2008-09-25       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.